We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$31.1B
AUM Growth
+$1.68B
Cap. Flow
+$21M
Cap. Flow %
0.07%
Top 10 Hldgs %
14.12%
Holding
3,080
New
66
Increased
2,426
Reduced
529
Closed
46

Top Buys

Rank Stock Value
1
CB icon
Chubb
CB
+$39M
2
HPE icon
Hewlett Packard
HPE
+$35.3M
3
SYF icon
Synchrony
SYF
+$29.5M
4
CMCSA icon
Comcast
CMCSA
+$25.4M
5
ILMN icon
Illumina
ILMN
+$13.5M

Sector Composition

Rank Sector Weight
1 Financials 15.31%
2 Healthcare 14.62%
3 Technology 14.1%
4 Industrials 10.66%
5 Consumer Discretionary 9.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VPG icon
2701
Vishay Precision Group
VPG
$1.02B
$239K ﹤0.01%
21,085
+640
+3% +$7.6K
KDNY
2702
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$238K ﹤0.01%
+1,692
New +$230K
AMX icon
2703
America Movil
AMX
$72.1B
$237K ﹤0.01%
16,880
-3,000
-15% -$49K
CVEO icon
2704
Civeo
CVEO
$356M
$237K ﹤0.01%
13,916
+1,471
+12% +$32.3K
PBPB
2705
DELISTED
Potbelly
PBPB
$237K ﹤0.01%
20,222
+2,030
+11% +$23.7K
GLF
2706
DELISTED
GulfMark Offshore, Inc. Common Stock
GLF
$237K ﹤0.01%
50,735
+3,995
+9% +$24.4K
GHM icon
2707
Graham Corp
GHM
$1.24B
$236K ﹤0.01%
14,015
+450
+3% +$7.88K
QNST icon
2708
QuinStreet
QNST
$889M
$236K ﹤0.01%
55,049
+1,985
+4% +$10.4K
RXII
2709
DELISTED
GALENA BIOPHARMA INC COM
RXII
$236K ﹤0.01%
160,845
+14,850
+10% +$21.8K
UCTT
2710
Ultra Clean Holdings
UCTT
$3.71B
$235K ﹤0.01%
45,928
+1,675
+4% +$8.66K
RGLS
2711
DELISTED
Regulus Therapeutics
RGLS
$234K ﹤0.01%
224
+13
+6% +$13K
WINA icon
2712
Winmark
WINA
$1.28B
$234K ﹤0.01%
2,519
+124
+5% +$12K
MBVT
2713
DELISTED
Merchants Bancshares Inc
MBVT
$234K ﹤0.01%
7,437
+290
+4% +$9.03K
UNTD
2714
DELISTED
UNITED ONLINE INC COM NEW
UNTD
$233K ﹤0.01%
19,801
+710
+4% +$8.01K
PRTK
2715
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$232K ﹤0.01%
12,217
+1,810
+17% +$34.5K
CCXI
2716
DELISTED
ChemoCentryx, Inc.
CCXI
$232K ﹤0.01%
28,635
+2,120
+8% +$15K
KLIC icon
2717
Kulicke & Soffa
KLIC
$4.96B
$231K ﹤0.01%
19,802
+1,550
+8% +$16.9K
PLPC icon
2718
Preformed Line Products
PLPC
$2.3B
$231K ﹤0.01%
+5,483
New +$228K
STRT icon
2719
STRATTEC Security
STRT
$372M
$231K ﹤0.01%
4,097
+285
+7% +$17.6K
VTAE
2720
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$231K ﹤0.01%
12,736
+1,855
+17% +$25.5K
KCLI
2721
DELISTED
KANSAS CITY LIFE INS CO NEW (MO)
KCLI
$230K ﹤0.01%
6,005
-393
-6% -$18.8K
FMS icon
2722
Fresenius Medical Care
FMS
$12.8B
$229K ﹤0.01%
5,466
+327
+6% +$13.8K
TPST icon
2723
Tempest Therapeutics
TPST
$14.7M
$229K ﹤0.01%
8
+1
+14% +$33K
CLD
2724
DELISTED
Cloud Peak Energy Inc
CLD
$229K ﹤0.01%
110,017
+9,740
+10% +$27.4K
ARMH
2725
DELISTED
ARM HOLDINGS PLC ADS
ARMH
$229K ﹤0.01%
5,070
+157
+3% +$7.41K

Similar funds

RhumbLine Advisers's Q4 2015 Portfolio in Review

As of Q4 2015, RhumbLine Advisers held 3,080 positions worth $31.1B, up 5.7% from $29.4B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Trading was light in Q4 2015: portfolio turnover was 3.6%. RhumbLine Advisers opened 66 new positions and exited 46, leaving the 3,080-position portfolio largely intact.

By sector, the portfolio is most concentrated in Financials at 15% of assets, down from 15% a quarter earlier, followed by Healthcare and Technology.

  • RhumbLine Advisers's largest Q4 2015 buy was Hewlett Packard: 4,220,807 shares worth $37.3M.
  • RhumbLine Advisers added most to Chubb in Q4 2015, an estimated $39M increase.
  • RhumbLine Advisers's biggest Q4 2015 reduction was HP, cutting an estimated $38.8M.
  • RhumbLine Advisers fully exited CHUBB CORPORATION in Q4 2015, selling an estimated $43M.
  • RhumbLine Advisers's ten largest holdings make up 14% of its $31.1B portfolio in Q4 2015.
  • RhumbLine Advisers opened 66 new positions and closed 46 in Q4 2015.
  • RhumbLine Advisers's portfolio value rose 5.7% quarter-over-quarter to $31.1B.

Based on RhumbLine Advisers's 13F filing for Q4 2015, filed 3 Feb 2016.